Julian Adams

34.1k total citations · 10 hit papers
168 papers, 21.4k citations indexed

About

Julian Adams is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Julian Adams has authored 168 papers receiving a total of 21.4k indexed citations (citations by other indexed papers that have themselves been cited), including 107 papers in Molecular Biology, 39 papers in Oncology and 34 papers in Genetics. Recurrent topics in Julian Adams's work include Ubiquitin and proteasome pathways (48 papers), Evolution and Genetic Dynamics (23 papers) and Cancer-related Molecular Pathways (20 papers). Julian Adams is often cited by papers focused on Ubiquitin and proteasome pathways (48 papers), Evolution and Genetic Dynamics (23 papers) and Cancer-related Molecular Pathways (20 papers). Julian Adams collaborates with scholars based in United States, Canada and Australia. Julian Adams's co-authors include Peter J. Elliott, Vito J. Palombella, Michael Kauffman, Paul G. Richardson, Christine Pien, Teru Hideshima, Charlotte E. Paquin, D Chauhan, K C Anderson and Edward A. Sausville and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

Julian Adams

168 papers receiving 20.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

2001 1.2k citations Vito J. Palombella, Julian Adams et al. PubMed profile →
Proteasome inhibitors: a novel class of potent and effective antitumor agents.

1999 1.2k citations Julian Adams, Vito J. Palombella et al. PubMed profile →
The proteasome: a suitable antineoplastic target

2004 992 citations Julian Adams profile →
NF-κB as a Therapeutic Target in Multiple Myeloma

2002 752 citations Vito J. Palombella, Julian Adams et al. Journal of Biological Chemistry profile →
Inhibition of HIV-1 Replication by a Nonnucleoside Reverse Transcriptase Inhibitor

1990 653 citations Vincent J. Merluzzi, Karl D. Hargrave et al. profile →
The development of proteasome inhibitors as anticancer drugs

2004 644 citations Julian Adams Cancer Cell profile →
Phase I Trial of the Proteasome Inhibitor PS-341 in Patients With Refractory Hematologic Malignancies

2002 586 citations Julian Adams et al. profile →
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

2004 569 citations James R. Berenson, Julian Adams et al. profile →
Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids

1998 543 citations Julian Adams, Louis Grenier et al. profile →
Development of the Proteasome Inhibitor Velcade™ (Bortezomib)

2004 537 citations Julian Adams et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Julian Adams United States	69	14.2k	6.2k	4.8k	2.4k	2.3k	168	21.4k
Edward A. Sausville United States	92	19.3k 1.4×	11.7k 1.9×	2.1k 0.4×	3.4k 1.4×	1.5k 0.6×	329	30.9k
Stefan Knapp Germany	91	21.6k 1.5×	5.6k 0.9×	3.9k 0.8×	1.1k 0.5×	1.4k 0.6×	516	29.0k
Steven Grant United States	79	16.7k 1.2×	6.3k 1.0×	3.6k 0.8×	2.3k 1.0×	825 0.4×	451	23.2k
Kapil N. Bhalla United States	87	17.3k 1.2×	5.9k 1.0×	6.5k 1.4×	2.2k 0.9×	940 0.4×	378	26.0k
Scott H. Kaufmann United States	95	25.8k 1.8×	11.9k 1.9×	3.2k 0.7×	3.7k 1.5×	1.6k 0.7×	406	36.2k
Charles Dumontet France	69	9.2k 0.6×	8.6k 1.4×	2.2k 0.5×	1.9k 0.8×	643 0.3×	377	20.7k
Ricky W. Johnstone Australia	77	18.7k 1.3×	7.8k 1.3×	2.0k 0.4×	2.2k 0.9×	1.3k 0.6×	248	25.4k
Paul A. Marks United States	72	17.9k 1.3×	4.6k 0.7×	2.2k 0.5×	1.0k 0.4×	1.5k 0.7×	202	22.6k
Andrew L. Kung United States	81	16.6k 1.2×	6.6k 1.1×	4.1k 0.9×	4.6k 1.9×	1.4k 0.6×	285	24.2k
Nathanael S. Gray United States	104	30.5k 2.2×	10.9k 1.8×	3.4k 0.7×	3.0k 1.3×	1.2k 0.5×	476	42.2k

Countries citing papers authored by Julian Adams

Since Specialization

Citations

This map shows the geographic impact of Julian Adams's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julian Adams with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julian Adams more than expected).

Fields of papers citing papers by Julian Adams

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julian Adams. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julian Adams. The network helps show where Julian Adams may publish in the future.

Co-authorship network of co-authors of Julian Adams

This figure shows the co-authorship network connecting the top 25 collaborators of Julian Adams. A scholar is included among the top collaborators of Julian Adams based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julian Adams. Julian Adams is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tillotson, Bonnie, Kelly L. Slocum, Brian D. Thomas, et al.. (2010). Hsp90 (Heat Shock Protein 90) Inhibitor Occupancy Is a Direct Determinant of Client Protein Degradation and Tumor Growth Arrest in Vivo. Journal of Biological Chemistry. 285(51). 39835–39843. 37 indexed citations

Adams, Julian, et al.. (2010). LTBP-2 has multiple heparin/heparan sulfate binding sites. Matrix Biology. 29(5). 393–401. 31 indexed citations

Ge, Jie, Emmanuel Normant, James R. Porter, et al.. (2006). Design, Synthesis, and Biological Evaluation of Hydroquinone Derivatives of 17-Amino-17-demethoxygeldanamycin as Potent, Water-Soluble Inhibitors of Hsp90. Journal of Medicinal Chemistry. 49(15). 4606–4615. 143 indexed citations

Waes, Carter Van, Angela A. Chang, Peter F. Lebowitz, et al.. (2005). Inhibition of nuclear factor-κB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. International Journal of Radiation Oncology*Biology*Physics. 63(5). 1400–1412. 93 indexed citations

Adams, Julian. (2005). Nuclear and Mitochondrial DNA in the Courtroom. eYLS (Yale Law School). 13(1). 5. 4 indexed citations

Adams, Julian. (2004). The development of proteasome inhibitors as anticancer drugs. Cancer Cell. 5(5). 417–421. 644 indexed citations breakdown →

Mark, Hans, Hank H. Yang, Kimberly M. Parker, et al.. (2003). The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.. PubMed. 9(3). 1136–44. 342 indexed citations

Adams, Julian. (2001). Proteasome inhibition in cancer: Development of PS-341. Seminars in Oncology. 28(6). 613–619. 146 indexed citations

Campbell, Barry J., Julian Adams, Yong Kyoo Shin, & Allan M. Lefer. (1999). Cardioprotective Effects of a Novel Proteasome Inhibitor Following Ischemia and Reperfusion in the Isolated Perfused Rat Heart. Journal of Molecular and Cellular Cardiology. 31(2). 467–476. 85 indexed citations

10.

Kelly, Tracy, John Proudfoot, Daniel W. McNeil, et al.. (1995). Novel Non-nucleoside Inhibitors of Human Immunodeficiency Virus Type 1 Reverse Transcriptase. 5. 4-Substituted and 2,4-Disubstituted Analogs of Nevirapine. Journal of Medicinal Chemistry. 38(24). 4839–4847. 32 indexed citations

11.

Rosenzweig, Ravid & Julian Adams. (1994). Microbial adaptation to a changeable environment: Cell‐cell interactions mediate physiological and genetic differentiation. BioEssays. 16(10). 715–717. 11 indexed citations

12.

Adams, Julian & Vincent J. Merluzzi. (1993). The search for antiviral drugs: case histories from concept to clinic.. Birkhäuser Boston eBooks. 14 indexed citations

13.

Wu, Joseph C., Thomas C. Warren, Julian Adams, et al.. (1991). A novel, dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a nonsubstrate binding site. Biochemistry. 30(8). 2022–2026. 158 indexed citations

14.

Adams, Julian, Marc‐André Poupart, & Louis Grenier. (1989). Diastereoselectivity in the Synthesis of 3(2H)-Furanones. Total Synthesis of (+)-Muscarine. Tetrahedron Letters. 30(14). 1753–1756. 39 indexed citations

15.

Adams, Julian, Marc‐André Poupart, Louis Grenier, et al.. (1989). Rhodium acetate catalyzes the addition of carbenoids α- to ether oxygens. Tetrahedron Letters. 30(14). 1749–1752. 101 indexed citations

16.

Helling, Robert B., et al.. (1987). Evolution of Escherichia coli During Growth in a Constant Environment. Genetics. 116(3). 349–358. 217 indexed citations

17.

Adams, Julian. (1983). The ionizing particle environment near earth. 21st Aerospace Sciences Meeting. 2 indexed citations

18.

Adams, Julian, Edward D. Rothman, & K. Beran. (1981). The age structure of populations of Saccharomyces cerevisiae. Mathematical Biosciences. 53(3-4). 249–263. 13 indexed citations

19.

Rastetter, William H., et al.. (1979). syn-2-ヒドロキシインダン3a,7a-オキシドの合成と化学. The Journal of Organic Chemistry. 44(18). 3175–3177. 3 indexed citations

20.

Adams, Julian & Paul E. Hansche. (1974). POPULATION STUDIES IN MICROORGANISMS I. EVOLUTION OF DIPLOIDY IN SACCHAROMYCES CEREVISIAE. Genetics. 76(2). 327–338. 67 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact